What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products, with FY26 revenue of Rs 641.29 crore. Operations are centred at a manufacturing site in Derabassi, Punjab, where a centralised warehouse with 11,000-pallet capacity is being built under an MOU worth about Rs 40 crore, adjoining the existing Global Business Unit. Overseas reach is supported through a Dubai subsidiary, identified as a recipient of fresh investment. The cost structure is materials-heavy, with raw materials at 42.4% of revenue and employees at 21.5%; other operating expenses add 27.4% and depreciation 4.8%. A Rs 137.20 crore preferential warrant issue to a promoter group entity is being put to shareholders, with Rs 53 crore earmarked for working capital, Rs 41.40 crore for further manufacturing and warehouse expansion, Rs 5 crore for the Dubai subsidiary, Rs 2 crore for R&D and Rs 1.5 crore for a technology upgrade. An earlier Rs 255.61 crore preferential warrant issue was deployed across business expansion, subsidiary investments, working capital and general corporate purposes.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from IND SWIFT LABORATORIES LT's filed financials and exchange disclosures
IND SWIFT LABORATORIES LT is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol INDSWFTLAB.
Yes. Over the trailing twelve months IND SWIFT LABORATORIES LT reported a net profit of ₹57 Cr on revenue of ₹665 Cr.
Not in the latest reported year — IND SWIFT LABORATORIES LT's dividend payout for FY26 was nil.
Effectively yes. It holds ₹412 Cr more cash than debt. Debt stands at 0.01× equity.
On trailing P/E, IND SWIFT LABORATORIES LT ranks 135 of 169 in Pharmaceuticals — cheaper than 20% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session IND SWIFT LABORATORIES LT moves 1.61% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by IND SWIFT LABORATORIES LT appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
